Denise Scots-KnightCEO and Founder at Mereo Biopharma Group plc
Denise is our CEO, a board member and co-founder of Mereo. Denise has over 25 years experience in the biopharmaceutical industry both in R&D management and as a venture capitalist. She started her career in R&D management at Amersham and Fisons and as a senior executive at Scientific Generics before joining Rothschild Asset Management as an investment manager. In 1999 she joined Nomura and became Managing Director after heading the life science investment team investing globally in biotechnology companies. She led the Phase4 Partners MBO from Nomura in 2010. Denise had served on many US and European private and public boards including Idenix (until acquired by Merck for $3.85bn). Denise has a PhD and BSc (Hons) from Birmingham University and was a Fulbright scholar at UC Berkeley.